BMRN vs PTGX: stock comparison and AI forecast
Biomarin Pharmaceutical Inc (BMRN) and Protagonist Therapeutics, Inc (PTGX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMRN Biomarin Pharmaceutical Inc
- Market Cap
- $10.86B
- P/E Ratio
- 561.2x
- Size
- large-cap
- AI Forecast
PTGX Protagonist Therapeutics, Inc
- Market Cap
- $8.75B
- P/E Ratio
- 171.2x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BMRN is 1.2 times larger than PTGX by market capitalization ($10.86B against $8.75B).
- PTGX trades at 171.2 times trailing earnings, BMRN at 561.2 times.
- BMRN carries 0.85 times debt per unit of equity, against 0.05 times for PTGX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMRN | PTGX |
|---|---|---|
| Market Cap | $10.86B | $8.75B |
| P/E Ratio | 561.21x | 171.21x |
| P/B Ratio | 1.74x | 10.40x |
| EPS | $0.10 | $0.79 |
| Book Value/Share | $32.32 | $13.01 |
| Revenue/Share | $18.88 | $3.49 |
| FCF/Share | $2.88 | $2.02 |
Profitability & Margins
| Metric | BMRN | PTGX |
|---|---|---|
| ROIC | 1.1% | 6.9% |
| Gross Margin | 76.0% | – |
| Operating Margin | 3.1% | 25.9% |
| EBT Margin | 1.2% | 36.4% |
| Tax Rate | 143.8% | 1.7% |
Financial Health
| Metric | BMRN | PTGX |
|---|---|---|
| Current Ratio | 2.44x | 21.71x |
| Quick Ratio | 1.32x | – |
| D/E Ratio | 0.85x | 0.05x |
| Financial Leverage | 1.85x | 1.05x |
| Working Capital | $2.32B | $770M |
Cash Flow
| Metric | BMRN | PTGX |
|---|---|---|
| Operating Cash Flow | $677M | $131M |
| Free Cash Flow | $558M | $131M |
| Capital Spending | -$119M | -$610K |
| OCF Growth YoY | -26.0% | 231.8% |
| FCF Growth YoY | -33.0% | 252.0% |
| FCF/Sales | 15.3% | 57.9% |
| CapEx/Sales | 3.2% | 0.3% |
Operational Efficiency
| Metric | BMRN | PTGX |
|---|---|---|
| Asset Turnover | 0.32x | 0.25x |
| Receivables Turnover | 3.4x | – |
| Inventory Turnover | 0.5x | – |
| Fixed Assets Turnover | 3.7x | 65.3x |
| Days Sales Outstanding | 107 days | – |
| Days Inventory | 746 days | – |
| Payables Period | 54 days | – |
| Cash Conversion Cycle | 799 days | – |
Income Statement
| Metric | BMRN | PTGX |
|---|---|---|
| Total Revenue | $3.66B | $226M |
| Operating Income | $114M | $58M |
| R&D Expense | $759M | $175M |
| SG&A Expense | $1.43B | – |
| Cost of Goods Sold | $879M | – |
Dividend & Shareholder Information
| Metric | BMRN | PTGX |
|---|---|---|
| Shares Outstanding | 194M | 65M |
| EPS Growth | -95.4% | -14.1% |
BMRN vs PTGX: stock comparison and AI forecast
Which is bigger, BMRN or PTGX?
BMRN is 1.2 times larger than PTGX by market capitalization ($10.86B against $8.75B).
Which is cheaper on earnings, BMRN or PTGX?
PTGX trades at 171.2 times trailing earnings, BMRN at 561.2 times.
Which one does Intratio's AI model rank higher, BMRN or PTGX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.